Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls.

COVID-19 Cancer Protection Sample pooling Strategy

Journal

Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559

Informations de publication

Date de publication:
24 Feb 2021
Historique:
received: 29 11 2020
accepted: 17 02 2021
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 26 2 2021
Statut: epublish

Résumé

Due to the worldwide COVID-19 outbreak it is mandatory for health care workers to develop containment strategies. Recently published data showed, that cancer patients might have a higher risk for severe course of the disease. We therefore developed a strategy of screening and containment for SARS-CoV-2 for hospitalized cancer patients. Our approach includes a temporary isolation in a so-called floating zone and testing strategy for screening of asymptomatic individuals by pooling of samples before RT-PCR amplification. Patients as far as health care professionals got tested twice a week. Nurses and physicians entered the floating zone with full body protection. Within 8 weeks we tested 418 individuals (professionals and patients) in total. Only 2 patients had COVID-19 without documented further transmission of SARS-CoV-2. We therefore think that our strategy might be a useful approach to protect inpatients with cancer at high risk for SARS-CoV-2 infection during this ongoing pandemic.

Identifiants

pubmed: 33627114
doi: 10.1186/s13027-021-00356-5
pii: 10.1186/s13027-021-00356-5
pmc: PMC7903402
doi:

Types de publication

Letter

Langues

eng

Pagination

17

Références

Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
J Clin Oncol. 2018 Aug 10;36(23):2395-2404
pubmed: 29856692
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Dominic Kaddu-Mulindwa (D)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany. dominic.kaddu@uks.eu.

Lorenz Thurner (L)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany.

Moritz Bewarder (M)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany.

Niels Murawski (N)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany.

Manfred Ahlgrimm (M)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany.

Thorsten Pfuhl (T)

Institute of Virology, Saarland University Medical Center, 66421, Homburg, Germany.

Barbara Gärtner (B)

Institute of Medical Microbiology and Hygiene, Saarland University Medical Center, 66421, Homburg, Germany.

Sigrun Smola (S)

Institute of Virology, Saarland University Medical Center, 66421, Homburg, Germany.

Stephan Stilgenbauer (S)

Department of Internal Medicine 1 (Oncology, Hematology, Rheumatology and Clinical Immunology), Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany.

Classifications MeSH